Serious fungal infections in Ecuador

  • J. Zurita
  • D. W. Denning
  • A. Paz-y-Miño
  • M. B. Solís
  • L. M. Arias
Original Article
Part of the following topical collections:
  1. Global Fungal Disease Burden

Abstract

There is a dearth of data from Ecuador on the burden of life-threatening fungal disease entities; therefore, we estimated the burden of serious fungal infections in Ecuador based on the populations at risk and available epidemiological databases and publications. A full literature search was done to identify all epidemiology papers reporting fungal infection rates. WHO, ONU-AIDS, Index Mundi, Global Asthma Report, Globocan, and national data [Instituto Nacional de Estadística y Censos (INEC), Ministerio de Salud Pública (MSP), Sociedad de Lucha Contra el Cáncer (SOLCA), Instituto Nacional de Donación y Trasplante de Órganos, Tejidos y Células (INDOT)] were reviewed. When no data existed, risk populations were used to estimate frequencies of fungal infections, using previously described methodology by LIFE. Ecuador has a variety of climates from the cold of the Andes through temperate to humid hot weather at the coast and in the Amazon basin. Ecuador has a population of 15,223,680 people and an average life expectancy of 76 years. The median estimate of the human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) population at risk for fungal disease (<200 CD4 cell counts) is ∼10,000, with a rate of 11.1% (1100) of histoplasma, 7% (700) of cryptococcal meningitis, and 11% (1070) of Pneumocystis pneumonia. The burden of candidemia is 1037. Recurrent Candida vaginitis (≥4 episodes per year) affects 307,593 women aged 15–50 years. Chronic pulmonary aspergillosis probably affects ∼476 patients following tuberculosis (TB). Invasive aspergillosis is estimated to affect 748 patients (∼5.5/100,000). In addition, allergic bronchopulmonary aspergillosis (ABPA) in asthma and severe asthma with fungal sensitization (SAFS) were estimated to affect 26,642 and 45,013 people, respectively. Our estimates indicate that 433,856 (3%) of the population in Ecuador is affected by serious fungal infection.

Notes

Compliance with ethical standards

Conflict of interest

JZ, DWD, APyM, MBD, LMA: nothing to declare.

References

  1. 1.
    Index Mundi (2014) Ecuador demographics profile 2014. Available online at: http://www.indexmundi.com/ecuador/demographics_profile.html. Accessed 5 Nov 2015
  2. 2.
    Ollague Sierra JE, Ollague Torres JM (2013) New clinical and histological patterns of acute disseminated histoplasmosis in human immunodeficiency virus-positive patients with acquired immunodeficiency syndrome. Am J Dermatopathol 35(2):205–212CrossRefPubMedGoogle Scholar
  3. 3.
    Ramos-E-Silva M, Saraiva Ldo E (2008) Paracoccidioidomycosis. Dermatol Clin 26(2):257–269CrossRefPubMedGoogle Scholar
  4. 4.
    Gil-Brusola A, Pemán J, Santos M, Salavert M, Lacruz J, Gobernado M (2007) Disseminated histoplasmosis with hemophagocytic syndrome in a patient with AIDS: description of one case and review of the Spanish literature. Rev Iberoam Micol 24(4):312–316CrossRefPubMedGoogle Scholar
  5. 5.
    Müller-Stöver I, Tintelnot K, Richter J, Häussinger D (2014) A 55-year-old woman with cough, fever, swelling of joints, and exanthema after a trip to Ecuador. Internist (Berl) 55(8):976–980CrossRefGoogle Scholar
  6. 6.
    Wolff M (1999) Outbreak of acute histoplasmosis in Chilean travelers to the ecuadorian jungle: an example of geographic medicine. Rev Med Chil 127(11):1359–1364CrossRefPubMedGoogle Scholar
  7. 7.
    Leading International Fungal Education (LIFE). Available online at: http://www.life-worldwide.org/fungal-diseases. Accessed 12 Dec 2015
  8. 8.
    Coyle PV, McCaughey C, Nager A, McKenna J, O’Neill H, Feeney SA, Fairley D, Watt A, Cox C, Curran T (2012) Rising incidence of Pneumocystis jirovecii pneumonia suggests iatrogenic exposure of immune-compromised patients may be becoming a significant problem. J Med Microbiol 61:1009–1015CrossRefPubMedGoogle Scholar
  9. 9.
    Ruhnke M, Groll AH, Mayser P, Ullmann AJ, Mendling W, Hof H, Denning DW; University of Manchester in association with the LIFE program (2015) Estimated burden of fungal infections in Germany. Mycoses 58(Suppl 5):22–28CrossRefPubMedGoogle Scholar
  10. 10.
    McKenney J, Smith RM, Chiller TM, Detels R, French A, Margolick J, Klausner JD; Centers for Disease Control and Prevention (2014) Prevalence and correlates of cryptococcal antigen positivity among AIDS patients—United States, 1986–2012. Clin Infect Dis 63(27):585–587Google Scholar
  11. 11.
    Gazzard BG, Smith D (1990) Oral candidosis in HIV-infected patients. Br J Clin Pract Suppl 71:103–108PubMedGoogle Scholar
  12. 12.
    Matee MI, Scheutz F, Moshy J (2000) Occurrence of oral lesions in relation to clinical and immunological status among HIV-infected adult Tanzanians. Oral Dis 6:106–111CrossRefPubMedGoogle Scholar
  13. 13.
    Patton LL, McKaig R, Strauss R, Rogers D, Eron JJ Jr (2000) Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 89:299–304CrossRefPubMedGoogle Scholar
  14. 14.
    Smith E, Orholm M (1990) Trends and patterns of opportunistic diseases in Danish AIDS patients 1980–1990. Scand J Infect Dis 22:665–672CrossRefPubMedGoogle Scholar
  15. 15.
    Buchacz K, Baker RK, Palella FJ Jr, Chmiel JS, Lichtenstein KA, Novak RM, Wood KC, Brooks JT; HOPS Investigators (2010) AIDS-defining opportunistic illnesses in US patients, 1994–2007: a cohort study. AIDS 24:1549–1559CrossRefPubMedGoogle Scholar
  16. 16.
    Nucci M, Queiroz-Telles F, Alvarado-Matute T, Tiraboschi IN, Cortes J, Zurita J, Guzman-Blanco M, Santolaya ME, Thompson L, Sifuentes-Osornio J, Echevarria JI, Colombo AL; Latin American Invasive Mycosis Network (2013) Epidemiology of candidemia in Latin America: a laboratory-based survey. PLoS One 8(3):e59373CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Pfaller MA, Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20(1):133–163CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Eggimann P, Que YA, Revelly JP, Pagani JL (2015) Preventing invasive candida infections. Where could we do better? J Hosp Infect 89(4):302–308CrossRefPubMedGoogle Scholar
  19. 19.
    Denning DW, Pleuvry A, Cole DC (2011) Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull World Health Organ 89:864–872CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Smith NL, Denning DW (2011) Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J 37:865–872CrossRefPubMedGoogle Scholar
  21. 21.
    Global Asthma Network, International Union Against Tuberculosis and Lung Diseases (2014) The global asthma report 2014. Available online at: http://www.globalasthmareport.org/burden/burden.php. Accessed 26 Oct 2015
  22. 22.
    Denning DW, Pleuvry A, Cole DC (2013) Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med Mycol 51:361–370CrossRefPubMedGoogle Scholar
  23. 23.
    Denning DW, Pashley C, Hartl D, Wardlaw A, Godet C, Del Giacco S, Delhaes L, Sergejeva S (2014) Fungal allergy in asthma-state of the art and research needs. Clin Transl Allergy 4:14CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Cueva P, Yérez J (2009) National Cancer Registry: Cancer Epidemiology in Quito 2003–2005, 15rd. Sociedad de Lucha contra el Cáncer, QuitoGoogle Scholar
  25. 25.
    San Sebastián M, Hurtig AK (2004) Cancer among indigenous people in the Amazon Basin of Ecuador, 1985–2000. Rev Panam Salud Publica 16(5):328–333PubMedGoogle Scholar
  26. 26.
    Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2012) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase. Lyon, France: International Agency for Research on Cancer; 2013. Available online at: http://globocan.iarc.fr. Accessed 24 Jun 2016
  27. 27.
    Lortholary O, Gangneux JP, Sitbon K, Lebeau B, de Monbrison F, Le Strat Y, Coignard B, Dromer F, Bretagne S; French Mycosis Study Group (2011) Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005–2007). Clin Microbiol Infect 17:1882–1889CrossRefPubMedGoogle Scholar
  28. 28.
    Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, Anaissie EJ, Brumble LM, Herwaldt L, Ito J, Kontoyiannis DP, Lyon GM, Marr KA, Morrison VA, Park BJ, Patterson TF, Perl TM, Oster RA, Schuster MG, Walker R, Walsh TJ, Wannemuehler KA, Chiller TM (2010) Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 50:1101–1111CrossRefPubMedGoogle Scholar
  29. 29.
    Ministerio de Salud Pública del Ecuador (2016) Instituto Nacional de Donación y Trasplante de Órganos, Tejidos y Células. Home page at: http://www.donaciontrasplante.gob.ec/indot. Accessed 15 Apr 2016
  30. 30.
    Foxman B, Muraglia R, Dietz JP, Sobel JD, Wagner J (2013) Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J Low Genit Tract Dis 17:340–345CrossRefPubMedGoogle Scholar
  31. 31.
    Douce R, Maldonado D, Vásconez O, Zurita J (2002) Histoplasmosis opportunistic infection common in Ecuador. VozAndes 14(1):48–51Google Scholar
  32. 32.
    Ortega D, Zambrano J (2012) Frequency Histoplasma capsulatum infection and associated risk factors in people living with the HIV/AIDS comprehensive care units of general hospital Dr. Enrique Garcés Hospital and Dr. Eugenio Espejo specialty from 2003 to 2012. Thesis for obtaining medical degree, PUCEGoogle Scholar
  33. 33.
    Mirza SA, Phelan M, Rimland D, Graviss E, Hamill R, Brandt ME, Gardner T, Sattah M, de Leon GP, Baughman W, Hajjeh RA (2003) The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992–2000. Clin Infect Dis 36:789–794CrossRefPubMedGoogle Scholar
  34. 34.
    To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, Boulet LP (2012) Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health 12:204CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Data of COPD. Available online at: http://www.ecuadorencifras.gob.ec/camas-y-egresos-hospitalarios/. Accessed Jun 2014
  36. 36.
    UNAIDS (2015) HIV and AIDS estimates 2015. Available online at: http://www.unaids.org/en/regionscountries/countries/ecuador. Accessed 25 Jun 2016
  37. 37.
    Denning DW, O’Driscoll BR, Hogaboam CM, Bowyer P, Niven RM (2006) The link between fungi and severe asthma: a summary of the evidence. Eur Respir J 27(3):615–626CrossRefPubMedGoogle Scholar
  38. 38.
    Vaca M, Guadalupe I, Erazo S, Tinizaray K, Chico ME, Cooper PJ, Hay P (2010) High prevalence of bacterial vaginosis in adolescent girls in a tropical area of Ecuador. BJOG 117(2):225–228CrossRefPubMedGoogle Scholar
  39. 39.
    Rodriguez A, Vaca M, Oviedo G, Erazo S, Chico ME, Teles C, Barreto ML, Rodrigues LC, Cooper PJ (2011) Urbanisation is associated with prevalence of childhood asthma in diverse, small rural communities in Ecuador. Thorax 66(12):1043–1050. doi:10.1136/thoraxjnl-2011-200225 CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    C&T Science and Work (2007) Occupational asthma: an invisible and growing social problem. Available online at: http://www.saudeetrabalho.com.br/download/asma-mantilla.pdf. Accessed Feb 2015
  41. 41.
    Ministerio de Salud Pública (2013) 235 millones de personas en el mundo padecen asma. Available online at: http://instituciones.msp.gob.ec/somossalud/index.php/enterate/246-235-millones-de-personas-en-el-mundo-padecen-asma. Accessed Jan 2015

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • J. Zurita
    • 1
    • 2
  • D. W. Denning
    • 3
  • A. Paz-y-Miño
    • 2
  • M. B. Solís
    • 2
  • L. M. Arias
    • 1
  1. 1.Facultad de MedicinaPontificia Universidad Católica del EcuadorQuitoEcuador
  2. 2.Unidad de Investigaciones en BiomedicinaZurita & Zurita LaboratoriosQuitoEcuador
  3. 3.National Aspergillosis CentreUniversity Hospital of South Manchester and University of ManchesterManchesterUK

Personalised recommendations